August 10, 2020 8:05am

While last week’s sector performance was sporadic

Pre-open indications: 1 BUY and 1 Maintain SELL

Earnings: Voyage Therapeutics (VYGR) and Sage Therapeutics (SAGE)

What I provide is an intelligence daily. RMi outlines the potential prelude to the daily dosage of facts and objectivity! Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!

My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

Dow futures are UP +0.35% (+95 points), S&P futures are UP +0.07% (-2.50 points) and NASDAQ futures are DOWN -0.01% (-1.25 points)

 

U.S. stock futures were mixed early Monday morning after President Trump signed several executive orders aimed at extending coronavirus relief;

  • Trump’s moves come after congressional leaders failed to make progress on a new coronavirus stimulus package last week.

European stocks advanced even with diminished investor sentiment due to U.S. – China tensions as the pan-European Stoxx 600 climbed 0.5% by late morning;

Asia Pacific markets traded mostly higher but investors remained cautious over heightened U.S.-China tensions, while markets in Japan are closed Monday for a public holiday.

 

Henry’omics:

The bigger question for markets is whether these recent actions will affect the US-China trade talks on August 15.

 

Friday night’s post title – “: anxiety was overcome as the oversold got supported; the question continues, are we pre-booked on the roller-coaster?”

  • The NASDAQ closed DOWN -97.09 points (-0.87%);
  • The IBB closed down -0.39% and XBI also closed up +0.10%
  • Sector volume was LOW with 1 of the 21-upside having higher than the 3-month average volume and the 2 of 11-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.44 points or -1.94% at 22.21;
  • Friday’s percentage (%) of the 21-upside were +0.17% (MDXG) to +8% (BSTG) while the 11-downside ranged -0.34% (GBT) to -5.78% (EDIT); 

Last five (5) sessions:

  • Friday closed positive with 21 advancers, 11 decline and 3 flats
  • Thursday closed negative with 11 advancers, 23 decline and 1 flat
  • Wednesday closed positive with 19 advancers, 15 decline and 1 flat
  • Tuesday closed negative with 13 advancers, 20 decline and 2 flats
  • Last Monday (8/3) closed positive with 31 advancers, 1 decline and 3 flats

Q3 so far:

  • August, 3 positive closes and 2 negative closes
  • July -11 positive and 11 negative closes with 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed up +$0.20 to $2.70 with 395 shares traded after Thursday’s +$0.32 to $2.50 after Wednesday’s +$2.18, Tuesday’s -$2.12 and last Monday’s $2.13 as “someone is STUFFING the purchase” of shares to keep the listed shares up in down sessions.

Remember, there are millions of private placement millions unregistered shares (priced at $3.20, $3.60 and $3.70) existing FAR beyond the outstanding shares with more coming …

Mrs. bin Zhao, the major stock holder and head of DST Capital, BSTG’s funder: if you had stuck to the original turn-around plan, BSTG would NOT be in this position! YOU will also be held RESPONSIBLE if and WHEN the Feds step-in.

Following up, “President Trumps’ recent executive order took direct aim directly at WeChat, which has more than 1 billion users worldwide, and whose “data collection threatens to allow the Chinese Communist Party access to Americans’ personal and proprietary information,” according to the order. Who and how are BSTG’s VPs going to communicate with now … to refinance?

  • Facts are irrefutable and the First amendment of the U.S. Constitution protects American’s free speech.

BUY:

Pluristem (PSTI) closed down -$0.13 to $8.97 and has a positive +$0.36 or +4.01% positive pre-market indication after PSTI receives clearance to begin P2 trials in Germany. Germany’s health regulatory agency, the Paul Ehrlich Institute (PEI), has cleared the P2 clinical protocol for its study titled, “A Randomized, Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of severe COVID-19.” Forty (40) patients hospitalized with severe cases of COVID-19 complicated by Acute Respiratory Distress Syndrome (ARDS) will be enrolled in the study.

 

The BOTTOM LINE: I’m on vacation but, still watching!

The sector is what it is, until it isn’t and even then, it doesn’t seem to be…

Just like algorithms, rules-are-what-we-make-of-them. The take-away, don’t dwell on what’s happened but, learn the lesson of investing in those who define and meet short-term expectation

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.